Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer.
Journal
Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
23
08
2023
accepted:
04
09
2023
revised:
25
08
2023
medline:
30
10
2023
pubmed:
21
9
2023
entrez:
21
9
2023
Statut:
ppublish
Résumé
In patients with locally advanced cancer without distant metastases, the neoadjuvant setting presents a platform to evaluate new drugs. For mismatch repair proficient/microsatellite stable (pMMR/MSS) colon and rectal cancer, immunotherapy has shown limited efficacy. Herein, we report exceptional responses observed with neoadjuvant botensilimab (BOT), an Fc-enhanced next-generation anti-CTLA-4 antibody, alongside balstilimab (BAL; an anti-PD-1 antibody) in two patients with pMMR/MSS colon and rectal cancer. The histological pattern of rapid immune response observed ("inside-out" (serosa-to-mucosa) tumor regression) has not been described previously in this setting. Spatial biology analyses (RareCyte Inc.) reveal mechanisms of actions of BOT, a novel innate-adaptive immune activator. These observations have downstream implications for clinical trial designs using neoadjuvant immunotherapy and potentially sparing patients chemotherapy.
Identifiants
pubmed: 37731056
doi: 10.1038/s41388-023-02835-y
pii: 10.1038/s41388-023-02835-y
pmc: PMC10611560
doi:
Substances chimiques
balstilimab
1Q2QT5M7EO
Antibodies, Monoclonal, Humanized
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3252-3259Informations de copyright
© 2023. The Author(s).
Références
Ann Oncol. 2018 Aug 1;29(8):1861-1868
pubmed: 29945191
Crit Rev Oncol Hematol. 2021 Jan;157:103172
pubmed: 33278676
Cell. 2023 Jan 19;186(2):363-381.e19
pubmed: 36669472
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Nat Med. 2020 Apr;26(4):566-576
pubmed: 32251400
Nat Cancer. 2023 Jul;4(7):1036-1052
pubmed: 37349501
Nat Med. 2022 Apr;28(4):626-629
pubmed: 35347282
Surg Oncol Clin N Am. 1996 Jul;5(3):513-30
pubmed: 8829316
N Engl J Med. 2018 Mar 29;378(13):1177-1188
pubmed: 29590544
Nat Cancer. 2023 Jul;4(7):930-932
pubmed: 37495737
Ann Oncol. 2018 Aug 1;29(8):1853-1860
pubmed: 29982279
N Engl J Med. 2022 Jun 23;386(25):2363-2376
pubmed: 35660797
Cancer. 1994 Jun 1;73(11):2680-6
pubmed: 8194005